Roche Holding (SWX:ROG) - Aktienkurs, Nachrichten und Analyse

ROG Aktienübersicht

Die Roche Holding AG ist in den Bereichen Pharmazeutika und Diagnostika in Europa, Nordamerika, Lateinamerika, Asien, Afrika, Australien und Ozeanien tätig.

Über das Unternehmen

ROG grundlegende Analyse
Schneeflocken-Punktzahl
Bewertung	5/6
Künftiges Wachstum	3/6
Vergangene Leistung	4/6
Finanzielle Gesundheit	4/6
Dividenden	5/6

Belohnungen

63.5% unter unserer Schätzung des beizulegenden Zeitwerts gehandelt

Prognostiziertes Gewinnwachstum 8.54% pro Jahr

Zahlt eine zuverlässige Dividende von 3.87%

Im Vergleich zu Wettbewerbern und der Branche gut bewertet

Risikoanalyse

Hat einen hohen Schuldenstand

Roche Holding AG Wettbewerber

Novartis

SWX:NOVN

CHF 196.2b

Dottikon ES Holding

SWX:DESN

CHF 3.5b

AstraZeneca

LSE:AZN

UK£191.5b

Johnson & Johnson

NYSE:JNJ

US$350.9b

Preisentwicklung & Leistung

Übersicht über alle Höchststände, Veränderungen und Kursrückgänge für Roche Holding
Historische Aktienkurse
Aktueller Aktienkurs	CHF 249.50
52-Wochen-Hoch	CHF 277.90
52-Wochen-Tief	CHF 212.90
Beta	0.16
11 Monat Veränderung	8.67%
3 Monate Veränderung	8.62%
1 Jahr Veränderung	-8.78%
33 Jahre Veränderung	-28.62%
5 Jahre Veränderung	-10.64%
Veränderung seit IPO	855.94%

Aktuelle Nachrichten und Updates

Recent updates

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Apr 17

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Mar 06

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Feb 09

Aktionärsrenditen

	ROG	CH Pharmaceuticals	CH Markt
7D	-1.3%	0.3%	-0.3%
1Y	-8.8%	21.0%	2.8%

Rendite im Vergleich zur Industrie: ROG unter dem Niveau der Branche Swiss Pharmaceuticals , die im vergangenen Jahr eine Rendite von 19.2% erzielte.

Rendite vs. Markt: ROG hinter dem Markt Swiss zurück, der im vergangenen Jahr eine Rendite von 4.1 erzielte.

Preisvolatilität

Is ROG's price volatile compared to industry and market?
ROG volatility
ROG Average Weekly Movement	2.7%
Pharmaceuticals Industry Average Movement	3.3%
Market Average Movement	3.4%
10% most volatile stocks in CH Market	6.6%
10% least volatile stocks in CH Market	2.0%

Stabiler Aktienkurs: ROG hat in den letzten 3 Monaten keine nennenswerten Preisschwankungen aufgewiesen.

Volatilität im Zeitverlauf: ROGDie wöchentliche Volatilität (3%) ist im vergangenen Jahr stabil geblieben.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1896	103,605	Thomas Schinecker	www.roche.com

Die Roche Holding AG ist in den Bereichen Pharmazeutika und Diagnostika in Europa, Nordamerika, Lateinamerika, Asien, Afrika, Australien und Ozeanien tätig. Das Unternehmen bietet pharmazeutische Produkte in den therapeutischen Bereichen Anämie, Blut und solide Tumore, Dermatologie, Hämophilie, entzündliche und Autoimmunerkrankungen, neurologische Erkrankungen, Augenheilkunde, Atemwegserkrankungen und Transplantation. Das Unternehmen entwickelt auch Produkte für verschiedene therapeutische Bereiche.

Roche Holding AG's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Roche Holding im Vergleich zum Marktanteil des Unternehmens?
ROG grundlegende Statistiken
Marktanteil	CHF 201.50b
Gewinn(TTM)	CHF 11.50b
Umsatz(TTM)	CHF 60.44b

17.3x

Kurs-Gewinn-Verhältnis

3.3x

Kurs-Umsatz-Verhältnis

Ist ROG zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
ROG Gewinn- und Verlustrechnung (TTM)
Einnahmen	CHF 60.44b
Kosten der Einnahmen	CHF 15.60b
Bruttogewinn	CHF 44.84b
Sonstige Ausgaben	CHF 33.35b
Umsatz	CHF 11.50b

Zuletzt gemeldete Gewinne

Dec 31, 2023

Datum des nächsten Gewinnberichts

Jul 25, 2024

Gewinn per Aktie (EPS)	14.42
Bruttomarge	74.19%
Nettogewinnspanne	19.02%
Schulden/Eigenkapital-Verhältnis	88.0%

Wie hat sich ROG auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

3.8%

Aktuelle Dividendenrendite

67%

Ausschüttungsquote

ROG Aktienübersicht

Belohnungen

Risikoanalyse

Roche Holding AG Wettbewerber

SWX:NOVN

CHF 196.2b

SWX:DESN

CHF 3.5b

LSE:AZN

UK£191.5b

NYSE:JNJ

US$350.9b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Recent updates

Roche Holding AG to Report Q2, 2024 Results on Jul 25, 2024

Roche Announces the European Commission Grants Marketing Authorisation for OCREVUS (Ocrelizumab) Subcutaneous for the Treatment of Relapsing Multiple Sclerosis and Primary Progressive Multiple Sclerosis

Roche Launches New Highly-Sensitive Test to More Easily Diagnostic Patients Who May Have B-Cell Lymphoma

Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma

Roche Holding AG Announces U.S. Food and Drug Administration Accepted the New Drug Application and Granted Priority Review to Inavolisib, an Investigational, Oral Therapy, in Combination with Palbociclib (Ibrance®) and Fulvestrant

Roche Announces Management and Board Committee Changes

Roche Receives FDA Device Designation for Blood Test Measuring Lp(a)

Roche Reports Positive Phase I Results for Its Dual GLP-1/GIP Receptor Agonist CT-388 in People with Obesity

Roche Announces FDA Approval of One of the First HPV Self- Collection Solutions in the U.S., Expanding Access and Screening Options to Help Eliminate Cervical Cancer

Roche Holding AG Provides Earnings Guidance for the Year 2024

FDA Approves Roche’s Alecensa as the First Adjuvant Treatment for People with ALK-Positive Early-Stage Lung Cancer

Roche Holding AG Announces Data from the Phase III OCARINA II Study (S31.006) of OCREVUS®? (ocrelizumab)

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Receives FDA Breakthrough Device Designation for Blood Test to Support Early Alzheimer's Disease Diagnosis

Roche Receives FDA Approval for the First Molecular Test to Screen for Malaria in Blood Donors

Roche Holding AG, Annual General Meeting, Mar 12, 2024

Upcoming dividend of CHF9.60 per share

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche and Alnylam Report Positive Topline Results from the Phase II KARDIA-2 Study in People with Hypertension

Roche Announces FDA Approves Xolair as First and Only Medicine for Children and Adults with One or More Food Allergies

Roche Launches Three New Factor Xa Inhibitor Coagulation Tests to Meet Growing Patient Need

Roche Holding's (VTX:ROG) Shareholders Will Receive A Bigger Dividend Than Last Year

Roche Holding's (VTX:ROG) Soft Earnings Are Actually Better Than They Appear

Full year 2023 earnings: EPS and revenues miss analyst expectations

Dividend increased to CHF9.60

Roche Announces New 72-Week Data from Two Global Phase III Studies, BALATON and COMINO, Evaluating Vabysmo® (Faricimab) in Macular Edema Due to Branch and Central Retinal Vein Occlusion (BRVO and CRVO)

Roche Holding AG Proposes Dividend

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

Roche Holding AG (SWX:ROG) completed the acquisition of Carmot Therapeutics Inc. from a group of shareholders.

European Commission Approves Roche's Tecentriq SC, the EU's First PD-(L)1 Cancer Immunotherapy Subcutaneous Injection for Multiple Cancer Types

Market Cool On Roche Holding AG's (VTX:ROG) Earnings

Roche Holding AG to Report Fiscal Year 2023 Results on Feb 01, 2024

Roche Announces New Data from Its CD20xCD3 T-Cell Engaging Bispecific Antibody Programme Were Presented At the 65Th American Society of Hematology Annual Meeting & Exposition

Roche Announces New Data Reinforce the Benefit of Early Preventative Treatment with Hemlibra for Babies with Severe Haemophilia A

Roche Presents Positive Results from the Phase III INAVO120 Study Evaluating Inavolisib in Combination with Palbociclib and Fulvestrant as a First-Line Treatment for People with PIK3CA-Mutation

We Think Roche Holding (VTX:ROG) Can Stay On Top Of Its Debt

Roche Holding AG (SWX:ROG) entered into a definitive merger agreement to acquire Carmot Therapeutics Inc. from a group of shareholders for approximately $2.7 billion.

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Expands Hepatitis Diagnostics Portfolio to Help Clinicians Diagnose and Monitor Patients with Acute or Chronic Hepatitis B Infection

Roche Launches Automated Serology Hepatitis E Virus Tests, Including A Test to Detect Acute Hev Infections, Recommended in the New Who 2023 Essential Diagnostics List

Roche's Subcutaneous Injection of Tecentriq Recommends by the EU's CHMP for Multiple Cancer Types

Roche Announces its Elecsys NfL Test Receives FDA Breakthrough Device Designation from the U.S. Food and Drug Administration

Roche Announces EMBARK Trial in Duchenne Muscular Dystrophy

United States Food and Drug Administration Approves Roche's Vabysmo for the Treatment of Retinal Veinocclusion (RVO)

Roche Holding AG Confirms Outlook for 2023

Roche Announces Roche IL-6 Is the First Immunoassay Approved to Aid Sepsis Diagnosis in Newborns

Roche Announces New Clinical and Real-World Data for Orevus (Ocrelizumab)

Roche Holding AG Announces Late-Breaking Data from the Phase III Ocarina III Study as an Investigational Twice-Yearly, 10-Minute Subcutaneous Injection on Pharmacokinetic, Biomarker, and Mri Measures in Patients with Relapsing or Primary Progressive Multiple Sclerosis

Roche Presents Positive Results from the Primary Analysis of the Ongoing Rainbowfish Study Assessing the Efficacy and Safety of Evrysdi

Roche and Alnylam Report Positive Topline Results from Phase 2 Study Kardia-1 of Zilebesiran

Roche’S Alecensa Delivers Unprecedented Phase III Results for People with ALK-positive early-stage lung cancer

Roche Holding AG Tecentriq Becomes the First Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy Available to Patients in Great Britain, Reducing Treatment Time to Just Minutes

Is Roche Holding (VTX:ROG) A Risky Investment?

Roche Provides Update on Phase III Skyscraper-01 Study in PD-L1-High Metastatic Non-Small Cell Lung Cancer

New minor risk - Earnings quality

Roche Holding AG Confirms Earnings Guidance for the Year 2023

Roche Announces New Clinical and Real-World Data for Vabysmo at ASRS Reveal Improved Outcomes for People with Two Leading Causes of Vision Loss

Roivant Sciences Reportedly Near Deal to Sell Stomach Drug to Roche for over $7 Billion

Roche Announces Positive Phase III Results for Roche’s OCREVUS (ocrelizumab) Twice a Year, 10-minute Subcutaneous Injection in Patients with Multiple Sclerosis

Erträge & Einnahmen